Quick Answer
TuHURA Biosciences, Inc./NV reported Cash and Equivalents of $3.62 million for fiscal year 2025.
TuHURA Biosciences, Inc./NV Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $3.62M | -71.4% |
| 2024 | $12.66M | +157.8% |
| 2024 | $4.91M | +33.9% |
| 2023 | $3.67M | +138.8% |
| 2023 | $1.53M | -87.0% |
| 2022 | $11.78M | +11.8% |
| 2021 | $10.54M | +340.5% |
| 2020 | $2.39M | -35.7% |
| 2019 | $3.72M | -37.7% |
| 2018 | $5.97M | -9.3% |
| 2017 | $6.59M | +7.0% |
| 2016 | $6.16M | +251.0% |
| 2015 | $1.75M | -63.1% |
| 2014 | $4.76M | +15.1% |
| 2013 | $4.14M | -34.2% |
| 2013 | $6.28M | +35233.4% |
| 2012 | $17.8K | +18.4% |
| 2011 | $15.0K | -38.4% |
| 2010 | $24.4K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $2.70M | -10.7% | -68.3% |
| June 30, 2025 | $8.51M | +73.4% | +36.9% |
| March 31, 2025 | $6.22M | -2.1% | -50.9% |
| December 31, 2024 | $12.66M | +1823.6% | +319.1% |
| September 30, 2024 | $3.02M | +1298.1% | -38.5% |
| June 30, 2024 | $4.91M | +219.8% | -22.7% |
| March 31, 2024 | $6.35M | +108.6% | +865.2% |
| December 31, 2023 | $658.0K | -86.5% | +204.6% |
- TuHURA Biosciences, Inc./NV showed a decrease of -71.4% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2010–2025 period, TuHURA Biosciences, Inc./NV’s cash and equivalents has grown by 14751.1% (from $24.4 thousand to $3.62 million).
- The most recent figure is from TuHURA Biosciences, Inc./NV’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: